Current and investigational approaches for reversing established osteoporosis

D. B. Kimmel, D. M. Slovik, Nancy E Lane

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Osteoporosis is an adulthood disease that is usually marked by low bone mass and poor structure. The abilities of existing agents like estrogen, calcitonin, calcium, and bisphosphonates limit current treatment planning strategies. While they decrease fracture rate, they inhibit bone remodeling and only maintain or modestly improve existing bone mass and structure. Persons with osteoporotic fractures need approaches that induce marked skeletal improvement. Flouride offers hope, but more promising regulatory agents that stimulate formation to substantially improve bone mass and structure have enjoyed success in preclinical trials and are now in early clinical testing.

Original languageEnglish (US)
Pages (from-to)735-758
Number of pages24
JournalRheumatic Disease Clinics of North America
Volume20
Issue number3
StatePublished - 1994
Externally publishedYes

Fingerprint

Osteoporosis
Bone and Bones
Osteoporotic Fractures
Bone Remodeling
Diphosphonates
Calcitonin
Estrogens
Calcium

ASJC Scopus subject areas

  • Rheumatology

Cite this

Current and investigational approaches for reversing established osteoporosis. / Kimmel, D. B.; Slovik, D. M.; Lane, Nancy E.

In: Rheumatic Disease Clinics of North America, Vol. 20, No. 3, 1994, p. 735-758.

Research output: Contribution to journalArticle

@article{3b16f63a799848d5978d2ede5762e4b1,
title = "Current and investigational approaches for reversing established osteoporosis",
abstract = "Osteoporosis is an adulthood disease that is usually marked by low bone mass and poor structure. The abilities of existing agents like estrogen, calcitonin, calcium, and bisphosphonates limit current treatment planning strategies. While they decrease fracture rate, they inhibit bone remodeling and only maintain or modestly improve existing bone mass and structure. Persons with osteoporotic fractures need approaches that induce marked skeletal improvement. Flouride offers hope, but more promising regulatory agents that stimulate formation to substantially improve bone mass and structure have enjoyed success in preclinical trials and are now in early clinical testing.",
author = "Kimmel, {D. B.} and Slovik, {D. M.} and Lane, {Nancy E}",
year = "1994",
language = "English (US)",
volume = "20",
pages = "735--758",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Current and investigational approaches for reversing established osteoporosis

AU - Kimmel, D. B.

AU - Slovik, D. M.

AU - Lane, Nancy E

PY - 1994

Y1 - 1994

N2 - Osteoporosis is an adulthood disease that is usually marked by low bone mass and poor structure. The abilities of existing agents like estrogen, calcitonin, calcium, and bisphosphonates limit current treatment planning strategies. While they decrease fracture rate, they inhibit bone remodeling and only maintain or modestly improve existing bone mass and structure. Persons with osteoporotic fractures need approaches that induce marked skeletal improvement. Flouride offers hope, but more promising regulatory agents that stimulate formation to substantially improve bone mass and structure have enjoyed success in preclinical trials and are now in early clinical testing.

AB - Osteoporosis is an adulthood disease that is usually marked by low bone mass and poor structure. The abilities of existing agents like estrogen, calcitonin, calcium, and bisphosphonates limit current treatment planning strategies. While they decrease fracture rate, they inhibit bone remodeling and only maintain or modestly improve existing bone mass and structure. Persons with osteoporotic fractures need approaches that induce marked skeletal improvement. Flouride offers hope, but more promising regulatory agents that stimulate formation to substantially improve bone mass and structure have enjoyed success in preclinical trials and are now in early clinical testing.

UR - http://www.scopus.com/inward/record.url?scp=0027964358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027964358&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 735

EP - 758

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 3

ER -